This study was supported by research funding from the National Natural Science Foundation of China (82230006, 82300169, 81970130, 82470159, and U24A20678), the Overseas Expertise Introduction Project ...

Acute promyelocytic leukemia (APL) is classically driven by the PML-RARA fusion oncogene and characterized by a maturation arrest of myeloid precursors. Variant APL (vAPL) with alternative RARA ...

Patients who do not carry any of the aforementioned defining genetic alterations or whose pretreatment cytogenetic investigation fails are categorized into AML subtypes defined by differentiation. 7 ...

The three approved JAK inhibitors (ruxolitinib, fedratinib, and pacritinib) are the cornerstones of management for symptomatic myelofibrosis. Numerous novel agents in development for myelofibrosis, ...

Promyelocytic leukemia nuclear bodies (PML NBs) are multi-protein assemblies representing distinct sub-nuclear structures. As phase-separated molecular condensates, PML NBs exhibit liquid droplet-like ...

The APL2012 trial is currently the largest randomized, multicenter clinical study of APL based on ATRA-ATO treatment with risk stratification. We enrolled 855 newly diagnosed APL patients during ...

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2 The ...

Acute Promyelocytic Leukemia (APL) is one of the most curable leukemia which shows great sensitivity to all-trans retinoic acid (ATRA) although a small number of the patients present poor prognosis ...

All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide ...

Copyright: © 2013 Elsevier Ltd. Published by Elsevier Ltd. The outlook for patients with acute myeloid leukaemia has improved in the past 30 years. Unlike other ...